Nextage Therapeutics (XTAE:NXTG) Debt-to-Equity : -0.13 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics Debt-to-Equity?

Nextage Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.31 Mil. Nextage Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.07 Mil. Nextage Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₪-2.90 Mil. Nextage Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nextage Therapeutics's Debt-to-Equity or its related term are showing as below:

XTAE:NXTG' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.32 Med: -0.37 Max: 0.58
Current: -0.13

During the past 8 years, the highest Debt-to-Equity Ratio of Nextage Therapeutics was 0.58. The lowest was -5.32. And the median was -0.37.

XTAE:NXTG's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs XTAE:NXTG: -0.13

Nextage Therapeutics Debt-to-Equity Historical Data

The historical data trend for Nextage Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics Debt-to-Equity Chart

Nextage Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.48

0.58

-5.32

-0.37

-0.13

Nextage Therapeutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									-5.32	0.28	-0.37	-0.28	-0.13

Competitive Comparison of Nextage Therapeutics's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextage Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's Debt-to-Equity falls into.

Nextage Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nextage Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.308	+	0.07)	/	-2.9
	=	-0.13

Nextage Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.308	+	0.07)	/	-2.9
	=	-0.13

Nextage Therapeutics (XTAE:NXTG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nextage Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nextage Therapeutics (XTAE:NXTG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581

Website

http://www.m-medic.com

Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines

From GuruFocus

First Trust Global Portfolios Limited Announces Name Changes for Certain Sub-Funds of First Trust Global Funds plc

By Business Wire Business Wire • 01-29-2021